University of KwaZulu-Natal, Durban, South Africa.
Inkosi Albert Luthuli Central Hospital, Durban, South Africa.
Eur J Trauma Emerg Surg. 2024 Oct;50(5):2501-2508. doi: 10.1007/s00068-024-02639-z. Epub 2024 Aug 28.
Adequate access to antiretrovirals (ARV) has improved the longevity and quality of life of people living with the human immunodeficiency virus(HIV). Antiretrovirals are known to cause multiple drug-drug interactions. It was noted clinically that patients on ARVs appeared to be more difficult to sedate. This begs the question of the clinical impact of these drug interactions, should clinicians adjust sedative dosages when managing patients on ARVs? This study aimed to investigate the presence of and measure the differences in sedation and analgesic utilisation between polytrauma patients on ARVs and those not on ARVs.
This retrospective observational chart review included consecutive adult polytrauma patients admitted to the Trauma ICU IALCH between January 2016 and December 2019. HIV status and ARV use was documented. The total sedation per drug utilised at 24, 48 and 72-hour interval was calculated and tabulated accordingly. Drug utilisation was compared to ARV status.
A total of 216 adult polytrauma patients were included in the study. A total of 44 patients were HIV positive and 172 were HIV negative. Of the HIV positive patients 41 (93.2%) were on ARVs. Multiple comparisons were confirmed, however the primary analysis compared HIV negative patients with HIV positive patients on ARV. Total morphine, ketamine, midazolam and propofol doses were all numerically greater in patients on ARVs, although none of these reached statistical significance. The use of morphine rescue boluses during the first 72 h of ICU admission and the doses of ketamine and propofol on ICU day 3 were significantly greater in those on ARVs.
The data analysis showed that patients on ARVs required higher doses of some analgesia and sedation in ICU and lower doses of midazolam. This needs to be considered when sedating patients in a setting with a high HIV prevalence.
抗逆转录病毒药物(ARV)的充分应用提高了人类免疫缺陷病毒(HIV)感染者的寿命和生活质量。已知 ARV 会引起多种药物相互作用。临床上注意到,接受 ARV 治疗的患者似乎更难镇静。这就提出了一个问题,即这些药物相互作用的临床影响,如果临床医生在管理接受 ARV 治疗的患者时,是否应该调整镇静药物剂量?本研究旨在调查 ARV 治疗和未接受 ARV 治疗的多发伤患者镇静和镇痛药物使用情况,并测量其差异。
本回顾性观察性图表回顾研究纳入了 2016 年 1 月至 2019 年 12 月期间连续入住 IALCH 创伤 ICU 的成年多发伤患者。记录了 HIV 状态和 ARV 使用情况。计算并相应地列出了 24、48 和 72 小时间隔内每种药物的总镇静用量。比较了药物使用情况与 ARV 状态。
本研究共纳入 216 例成年多发伤患者。共有 44 例 HIV 阳性,172 例 HIV 阴性。HIV 阳性患者中,41 例(93.2%)正在服用 ARV。经多次比较确认,主要分析比较了 HIV 阴性患者和正在服用 ARV 的 HIV 阳性患者。接受 ARV 治疗的患者的吗啡、氯胺酮、咪达唑仑和丙泊酚总剂量均较高,尽管这些差异均无统计学意义。在 ICU 入住的前 72 小时内,使用吗啡解救剂量和 ICU 第 3 天使用氯胺酮和丙泊酚的剂量在接受 ARV 治疗的患者中明显更高。
数据分析显示,接受 ARV 治疗的患者在 ICU 中需要更高剂量的一些镇痛和镇静药物,以及更低剂量的咪达唑仑。在 HIV 流行率较高的环境中对患者进行镇静时,需要考虑到这一点。